AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11967517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive laboratory-based laparoscopic skills training curriculum
Number of subjects: 26
Study 11967517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formal practice sessions)
Number of subjects: 26
Study 11967517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (skills and control)
Number of subjects: 26
Study 9839766 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (10 mg day(-1)) administered for 19 consecutive days with a single dose of warfarin (25 mg) on day 14.
Number of subjects: 12
Study 9839766 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (25 mg) administered alone on day 14 after an initial 13-day period with no medication.
Number of subjects: 12
Study 9839766 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (10 mg day(-1)) administered for 19 days with an additional single dose of warfarin (25 mg) on day 41 after a washout period.
Number of subjects: 12
Study 7648286 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 2 mg Photofrin/kg and 120 J/cm2 laser light (n = 5)
Number of subjects: 8
Study 7648286 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 2 mg Photofrin/kg and 70 J/cm2 laser light (n = 4)
Number of subjects: 8
Study 7648286 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 2 mg Photofrin/kg
Number of subjects: 8
Study 2664886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabamate
Number of subjects: 60
Study 2664886 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 60
Study 70947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatimide (20 mg, two tablets three times a day for 2 weeks)
Number of subjects: 215
Study 70947 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine consumption
Number of subjects: 215
Study 30444690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill resin composite (Filtek Bulk-Fill Posterior Restorative)
Number of subjects: 51
Study 30444690 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite CAD/CAM inlays (Lava Ultimate)
Number of subjects: 51
Study 30444690 — intervention group
Group type: COMPARATOR
Intervention: Control group (intact teeth)
Number of subjects: 51
Study 29538697 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification tool for invasive melanoma
Number of subjects: 41954
Study 29538697 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification tool for all melanomas (invasive + in situ)
Number of subjects: 41954
Study 26190853 — intervention group
Group type: EXPERIMENTAL
Intervention: Four positions for intratracheal beractant administration (Group I)
Number of subjects: 125
Study 26190853 — intervention group
Group type: EXPERIMENTAL
Intervention: Two positions for intratracheal beractant administration (Group II)
Number of subjects: 125
Study 26190853 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral position for intratracheal beractant administration (Group III)
Number of subjects: 125
Study 24463668 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone follow-up with semiquantitative urine pregnancy test and symptom checklist
Number of subjects: 1433
Study 24463668 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone follow-up with semiquantitative urine pregnancy test
Number of subjects: 1433
Study 24463668 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative pregnancy test alone (without symptom checklist)
Number of subjects: 1433
Study 24463668 — intervention group
Group type: COMPARATOR
Intervention: Clinic follow-up
Number of subjects: 1433
Study 22357901 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of controlled-release oxycodone (CRO)
Number of subjects: 210
Study 22357901 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of controlled-release oxycodone (CRO)
Number of subjects: 210
Study 22357901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 20075530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (1 microg/kg)
Number of subjects: 30
Study 20075530 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 17601720 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidification during nasal NIV
Number of subjects: 16
Study 17601720 — intervention group
Group type: COMPARATOR
Intervention: Without heated humidification during nasal NIV
Number of subjects: 16
Study 15704510 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale (MAS) assessment with different stretching velocities
Number of subjects: 50
Study 15704510 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of contractures
Number of subjects: 50
Study 15704510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching velocity
Number of subjects: 50
Study 12490344 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (300-400 mg/day)
Number of subjects: 35
Study 10363537 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise (experimental group)
Number of subjects: 107
Study 10363537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation therapy)
Number of subjects: 107
Study 10363537 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent group (did not practice relaxation)
Number of subjects: 107
Study 8784215 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 0
Study 2144018 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion floxuridine (FUDR) at 0.15 mg/kg/d (IV) or 0.25 mg/kg/d (IA) for 14 days at monthly intervals.
Number of subjects: 68
Study 7316249 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Control Unit (ECU) treatment, where patients were taken off all medication and not fed until leg pain and swelling disappeared (4 to 7 days).
Number of subjects: 20
Study 7316249 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Control Unit (ECU) treatment with daily exercycle at 150 kpm for one mile to demonstrate absence of phlebitis.
Number of subjects: 20
Study 7316249 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulant regime, bed rest, and support hose (control group).
Number of subjects: 20
Study 7316249 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Control Unit (ECU) treatment.
Number of subjects: 20
Study 31230466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates method intervention (24 sessions over 12 weeks)
Number of subjects: 51
Study 31230466 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical treatment (control group)
Number of subjects: 51
Study 27616331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% plus dexmedetomidine 1mg/kg
Number of subjects: 0
Study 27616331 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.75% plus clonidine 1mg/kg
Number of subjects: 0
Study 27616331 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 0
Study 26453532 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 0
Study 26453532 — intervention group
Group type: COMPARATOR
Intervention: Traditional Nursing Care (TNC)
Number of subjects: 0
Study 25128296 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 88
Study 25128296 — intervention group
Group type: COMPARATOR
Intervention: Habitual Western diet (Control)
Number of subjects: 88
Study 21905981 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy (RP)
Number of subjects: 0
Study 19183128 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS stimulation
Number of subjects: 48
Study 19183128 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48
Study 17207174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 40
Study 17207174 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 40
Study 16368055 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg/day
Number of subjects: 446
Study 16368055 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day
Number of subjects: 446
Study 12174174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) diagnostic criteria based on neuropsychological tests and modified Clinical Dementia Rating (CDR) score of 0.5.
Number of subjects: 806
Study 12174174 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI diagnostic criteria
Number of subjects: 806
Study 9549743 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg-1)
Number of subjects: 100
Study 9549743 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (50 micrograms.kg-1)
Number of subjects: 100
Study 9549743 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.25 mg.kg-1)
Number of subjects: 100
Study 9549743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 7618677 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg droperidol added to 120 mg morphine in 60 ml saline
Number of subjects: 50
Study 1618244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg
Number of subjects: 6
Study 1618244 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 6
Study 1618244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 6
Study 1618244 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 6
Study 6734073 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 92 mmol/l
Number of subjects: 6
Study 6734073 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 272 mmol/l
Number of subjects: 6
Study 6734073 — intervention group
Group type: COMPARATOR
Intervention: Glucose 76 mmol/l
Number of subjects: 6
Study 6734073 — intervention group
Group type: COMPARATOR
Intervention: Glucose 215 mmol/l
Number of subjects: 6
Study 31404018 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 3 × 500 mg intravenously daily
Number of subjects: 98
Study 31404018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 31404018 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 98
Study 30289884 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video intervention (29-minute video with HIV-related health messages)
Number of subjects: 2023
Study 30289884 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients visiting clinics during the prior 10 months, N = 1,979)
Number of subjects: 2023
Study 26972646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (30 mg/m²) and Irinotecan (50 mg/m²) on day 1, 8, 22, 29 during 45 Gy radiation therapy (RT), 1.8 Gy per day over 5 weeks.
Number of subjects: 86
Study 26972646 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (30 mg/m²) and Paclitaxel (50 mg/m²) on day 1, 8, 15, 22, 29 with RT, followed by adjuvant cisplatin (75 mg/m²) and paclitaxel (175 mg/m²) day 1 every 21 days for 3 cycles.
Number of subjects: 86
Study 25545025 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-initiated condition
Number of subjects: 0
Study 25545025 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced condition
Number of subjects: 0
Study 25545025 — intervention group
Group type: COMPARATOR
Intervention: Look AHEAD Intensive Lifestyle Intervention (ILI)
Number of subjects: 0
Study 23992160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd‐YAG laser
Number of subjects: 15
Study 23992160 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 15
Study 20528705 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced GP care plus MoodGYM (internet-based CBT)
Number of subjects: 83
Study 20528705 — intervention group
Group type: COMPARATOR
Intervention: Enhanced GP care
Number of subjects: 83
Study 19138245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (100 microg)
Number of subjects: 66
Study 19138245 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 66
Study 16601402 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (170-425 mg once daily)
Number of subjects: 200
Study 16601402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 14551370 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAPES HF800
Number of subjects: 10
Study 14551370 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone
Number of subjects: 10
Study 14551370 — intervention group
Group type: COMPARATOR
Intervention: Polyamide
Number of subjects: 10
Study 10977791 — intervention group
Group type: EXPERIMENTAL
Intervention: The Life Readiness Program (6-month rehabilitation program, n = 39)
Number of subjects: 82
Study 10977791 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical management alone (control, n = 43)
Number of subjects: 82
Study 9409567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic enteral nutrition (CYC)
Number of subjects: 57
Study 9409567 — intervention group
Group type: COMPARATOR
Intervention: Continuous enteral nutrition (CON)
Number of subjects: 57
Study 8390559 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ganciclovir (10 mg/kg/day)
Number of subjects: 65
Study 8390559 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ganciclovir (10 mg/kg/day)
Number of subjects: 65
Study 2442558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (1.25‐10.0 mg) administered on days 1 and 3
Number of subjects: 24
Study 2442558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (oral and intravenous administration)
Number of subjects: 24
Study 30077866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart's Sonata for two pianos K.448
Number of subjects: 80
Study 30077866 — intervention group
Group type: EXPERIMENTAL
Intervention: Beethoven's Moonlight Sonata
Number of subjects: 80
Study 30077866 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartbeat sound recordings (70 bpm)
Number of subjects: 80
Study 30077866 — intervention group
Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 80
Study 27099270 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-phenethyl isothiocyanate (PEITC) supplementation
Number of subjects: 82
Study 27099270 — intervention group
Group type: COMPARATOR
Intervention: Control (smokers possessing both GSTM1 and GSTT1 genes)
Number of subjects: 82
Study 25196930 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 week individualized balance and strength home exercise program based on the Otago Exercise Program with additional exercises focused on improving turning ability.
Number of subjects: 0
Study 25196930 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control group).
Number of subjects: 0
Study 25196930 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 week individualized balance and strength home exercise program.
Number of subjects: 0
Study 22503720 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine (0.05 mg/kg BW, i.m.)
Number of subjects: 24
Study 22503720 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 20518174 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming moxibustion (added on Guanyuan (CV 4), Qihai (CV 6), and Pishu (BL 20))
Number of subjects: 94
Study 20518174 — intervention group
Group type: COMPARATOR
Intervention: Isotritinoin soft capsule (taken orally)
Number of subjects: 94
Study 20518174 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (control group 2)
Number of subjects: 94
Study 17309847 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 17309847 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxibs
Number of subjects: 0
Study 15685259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuli's grading system
Number of subjects: 33
Study 15685259 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIA scoring system
Number of subjects: 33
Study 12008199 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy to the chest wall and axilla (45 Gy in 15 fractions over 3 weeks)
Number of subjects: 76
Study 12008199 — intervention group
Group type: COMPARATOR
Intervention: No further loco-regional treatment (watch policy)
Number of subjects: 76
Study 12008199 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 76
Study 12008199 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 76
Study 7819652 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs) in a carbohydrate solution
Number of subjects: 0
Study 7819652 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink containing only carbohydrates
Number of subjects: 0
Study 2891798 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative RT plus chemotherapy with CAP (Cyclophosphamide, Adriamycin, and Cisplatin) for 6 months
Number of subjects: 172
Study 2891798 — intervention group
Group type: COMPARATOR
Intervention: Postoperative RT alone
Number of subjects: 172
Study 2891798 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative RT plus chemotherapy with CAP
Number of subjects: 172
Study 31531733 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE) countermeasure
Number of subjects: 12
Study 31531733 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (CON)
Number of subjects: 12
Study 31531733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt 80°
Number of subjects: 12
Study 28473464 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein ingestion during hyperinsulinemic-euglycemic clamp procedure (HECP)
Number of subjects: 30
Study 28473464 — intervention group
Group type: COMPARATOR
Intervention: Leucine ingestion during hyperinsulinemic-euglycemic clamp procedure (HECP)
Number of subjects: 30
Study 28473464 — intervention group
Group type: COMPARATOR
Intervention: No protein or leucine ingestion during hyperinsulinemic-euglycemic clamp procedure (HECP)
Number of subjects: 30
Study 25896566 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 48
Study 25896566 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 48
Study 23138609 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg clopidogrel loading dose
Number of subjects: 35
Study 23138609 — intervention group
Group type: COMPARATOR
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 35
Study 21747288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster Training (CT)
Number of subjects: 18
Study 21747288 — intervention group
Group type: COMPARATOR
Intervention: Traditional Training (TT)
Number of subjects: 18
Study 19464878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with sufentanil 0.5 microg/mL
Number of subjects: 53
Study 19464878 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine with sufentanil 0.5 microg/mL
Number of subjects: 53
Study 16683215 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of ACE (> 50 U/L)
Number of subjects: 184
Study 16683215 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of PAI-1 (> 43 ng/ml)
Number of subjects: 184
Study 16683215 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic agents with high ACE levels
Number of subjects: 184
Study 15108028 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Practice Guidelines for surveillance follow-up
Number of subjects: 0
Study 11797162 — intervention group
Group type: EXPERIMENTAL
Intervention: Misgav Ladach method
Number of subjects: 172
Study 11797162 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 172
Study 9223815 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms/d for 6 weeks)
Number of subjects: 44
Study 9223815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9223815 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 44
Study 8387067 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy with 50 Gy in 25 daily fractions over 5 weeks
Number of subjects: 161
Study 8387067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic therapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 161
Study 8387067 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 161
Study 8387067 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 161
Study 3293480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied during mask ventilation
Number of subjects: 50
Study 3293480 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure applied during mask ventilation
Number of subjects: 50
Study 3293480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied in difficult to ventilate patients
Number of subjects: 50
Study 31590692 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment of Vestibular Rehabilitation (VR) and Cognitive Behaviour Therapy (CBT) with eight sessions after a one-session Brief Intervention Vestibular Rehabilitation (BI-VR)
Number of subjects: 125
Study 31590692 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention Vestibular Rehabilitation (BI-VR)
Number of subjects: 125
Study 27621048 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide with oxygen (N2O/O2) via nasal mask, titrated to a maximum 70%:30% mixture during the procedure, with pre-procedure placebo pills.
Number of subjects: 72
Study 27621048 — intervention group
Group type: COMPARATOR
Intervention: Inhaled O2 during the procedure and 5/325 mg hydrocodone/acetaminophen and 1 mg lorazepam pre-procedure (active control).
Number of subjects: 72
Study 24100289 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400 μg)
Number of subjects: 49
Study 24100289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 23480276 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 80
Study 23480276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22471971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Triple P intervention (14-week program)
Number of subjects: 0